Please wait while we load the requested 10-Q report or click the link below:
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights
VY-AADC for advanced Parkinson’s disease on track for start of global, pivotal phase 2-3 program
Voyager further strengthens manufacturing and program teams with key leadership hires
Cambridge, Mass., November 2, 2017 – Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its third quarter of 2017 financial results and corporate highlights and will host a conference call and webcast today at 4:30 p.m. EDT to discuss these results.
“During the third quarter, we delivered strong progress with our Parkinson’s disease program including gaining worldwide rights, we continued to develop our pipeline programs, and we further progressed our novel capsid discovery efforts,” said Steve Paul, M.D., president and chief executive officer of Voyager Therapeutics. “Our global, pivotal program for VY-AADC remains on track, and we are excited to bring this important program one step closer to patients. In addition, we are encouraged by our recent data with our novel capsids and optimized dosing paradigms. Our innovative work in these areas has the potential to yield best-in-class programs and our updated timeline on our preclinical programs reflects a strong emphasis on optimizing capsid and vector delivery and moving only highly-targeted and differentiated candidates into the clinic.”
Recent Clinical and Preclinical Program Highlights and Updates
VY-AADC for advanced Parkinson’s disease:
During the third quarter, Voyager provided updated results to the ongoing Phase 1b trial with VY-AADC for advanced Parkinson’s disease and recently presented the results at the European Society of Gene and Cell Therapy (ESGCT) on October 18, 2017, in Berlin, Germany, and at the Michael J. Fox Foundation meeting on October 30, 2017 in New York City. The results demonstrated durable, dose-dependent and time-dependent improvements across multiple measures of patients’ motor function after a one-time administration of
The following information was filed by Voyager Therapeutics, Inc. (VYGR) on Thursday, November 2, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Voyager Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Voyager Therapeutics, Inc..